

Hisashi Hidaka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4383552/publications.pdf>

Version: 2024-02-01

43
papers

1,577
citations

361045

20
h-index

315357

38
g-index

44
all docs

44
docs citations

44
times ranked

1982
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. <i>Hepatology Research</i> , 2022, 52, 269-280.	1.8	28
2	Ultrasonography in the diagnosis of complications in patients with portal hypertension. <i>Journal of Medical Ultrasonics (2001)</i> , 2022, 49, 347-358.	0.6	1
3	Impact of Anti-GPIIb/IIIa Antibody-Producing B Cells as a Predictor of the Response to Lusutrombopag in Thrombocytopenic Patients with Liver Disease. <i>Digestive Diseases</i> , 2021, 39, 234-242.	0.8	7
4	Analysis of efficacy of lenvatinib treatment in highly advanced hepatocellular carcinoma with tumor thrombus in the main trunk of the portal vein or tumor with more than 50% liver occupation: A multicenter analysis. <i>Hepatology Research</i> , 2021, 51, 201-215.	1.8	22
5	A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1233-1239.	0.4	8
6	Evidence-based clinical practice guidelines for liver cirrhosis 2020. <i>Hepatology Research</i> , 2021, 51, 725-749.	1.8	90
7	Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. <i>Journal of Gastroenterology</i> , 2021, 56, 593-619.	2.3	158
8	Prospective study for an independent predictor of prognosis in liver cirrhosis based on the new sarcopenia criteria produced by the Japan Society of Hepatology. <i>Hepatology Research</i> , 2021, 51, 968-978.	1.8	12
9	Lusutrombopag has slightly stronger effects on patients with mild thrombocytopenia compared with those with severe thrombocytopenia: A multicenter propensity score matching study. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, , .	1.4	1
10	Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib. <i>Liver Cancer</i> , 2020, 9, 193-206.	4.2	57
11	<p>>Safety and Efficacy of Lenvatinib Treatment in ChildÁPugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis<p>>. <i>Clinical and Experimental Gastroenterology</i> , 2020, Volume 13, 385-396.	1.0	34
12	Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib. <i>Scientific Reports</i> , 2020, 10, 17054.	1.6	4
13	LongÁterm observation in patients with esophageal varices after endoscopic variceal ligation accompanied with 24Áhour pH monitoring. <i>Hepatology Research</i> , 2020, 50, 1255-1263.	1.8	1
14	Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study. <i>Hepatology Research</i> , 2020, 50, 1083-1090.	1.8	12
15	Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 293.	1.7	34
16	Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL). <i>Medical Oncology</i> , 2019, 36, 52.	1.2	9
17	Lusutrombopag Reduces Need for Platelet Transfusion in Patients With Thrombocytopenia Undergoing Invasive Procedures. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1192-1200.	2.4	92
18	Esophagogastric Varices in Liver Cirrhosis. , 2019, , 131-139.		0

#	ARTICLE	IF	CITATIONS
19	Antithrombin III for portal vein thrombosis in patients with liver disease: A randomized, double-blind, controlled trial. <i>Hepatology Research</i> , 2018, 48, E107-E116.	1.8	39
20	Prospective, randomized, controlled study of the efficacy of transcatheter arterial chemoembolization with miriplatin for hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, E98-E106.	1.8	7
21	Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 37-46.	3.7	127
22	Relationship between response to lusutrombopag and splenic volume. <i>World Journal of Gastroenterology</i> , 2018, 24, 5271-5279.	1.4	22
23	Effect of branched-chain amino acid supplements on muscle strength and muscle mass in patients with liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1402-1407.	0.8	36
24	Three-dimensional computed tomography of portopulmonary venous anastomoses in patients with esophageal varices before treatment. <i>Hepatology Research</i> , 2016, 46, 559-564.	1.8	6
25	Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma. <i>BMC Research Notes</i> , 2015, 8, 609.	0.6	30
26	Peliosis hepatis disseminated rapidly throughout the liver in a patient with prostate cancer: a case report. <i>Journal of Medical Case Reports</i> , 2015, 9, 194.	0.4	10
27	Intraperitoneal bleeding after balloon-occluded retrograde transvenous obliteration: a case report. <i>Journal of Medical Case Reports</i> , 2015, 9, 62.	0.4	1
28	Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis. <i>Hepatology Research</i> , 2015, 45, 279-287.	1.8	25
29	Early evaluation of response to sorafenib for hepatocellular carcinoma by duplex Doppler ultrasonography. <i>Hepatology Research</i> , 2015, 45, 976-985.	1.8	2
30	Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA) CC genotype caused by pegylated interferon (IFN)- α -2a with ribavirin therapy: a case report. <i>BMC Research Notes</i> , 2014, 7, 141.	0.6	3
31	Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. <i>BMC Gastroenterology</i> , 2014, 14, 84.	0.8	97
32	The efficacy of nocturnal administration of branched-chain amino acid granules to improve quality of life in patients with cirrhosis. <i>Journal of Gastroenterology</i> , 2013, 48, 269-276.	2.3	42
33	Total and viable residual splenic volume measurement after partial splenic embolization by three-dimensional ultrasound. <i>Journal of Medical Ultrasonics (2001)</i> , 2013, 40, 417-424.	0.6	1
34	Early increase in α -fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 683-689.	0.8	73
35	Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study. <i>Journal of Gastroenterology</i> , 2012, 47, 1030-1035.	2.3	27
36	Long-term administration of PPI reduces treatment failures after esophageal variceal band ligation: a randomized, controlled trial. <i>Journal of Gastroenterology</i> , 2012, 47, 118-126.	2.3	47

#	ARTICLE	IF	CITATIONS
37	A case of giant intramural hematoma of the esophagus after endoscopic injection sclerotherapy with ligation. <i>Progress of Digestive Endoscopy</i> , 2012, 81, 78-79.	0.0	0
38	Effects of 1-year administration of olmesartan on portal pressure and TGF-beta1 in selected patients with cirrhosis: a randomized controlled trial. <i>Journal of Gastroenterology</i> , 2011, 46, 1316-1323.	2.3	22
39	Reliability and validity of splenic volume measurement by 3D ultrasound. <i>Hepatology Research</i> , 2010, 40, 979-988.	1.8	14
40	Therapeutic benefits of partial splenic embolization for thrombocytopenia in hepatocellular carcinoma patients treated with radiofrequency ablation. <i>Hepatology Research</i> , 2009, 39, 772-778.	1.8	19
41	Radiofrequency Ablation of Hepatocellular Carcinoma: Correlation Between Local Tumor Progression After Ablation and Ablative Margin. <i>American Journal of Roentgenology</i> , 2007, 188, 480-488.	1.0	314
42	New angiotensin II type 1 receptor blocker olmesartan improves portal hypertension in patients with cirrhosis. <i>Hepatology Research</i> , 2007, 37, 1011-1017.	1.8	9
43	Restoration of thrombopoietin production after partial splenic embolization leads to resolution of thrombocytopenia in liver cirrhosis. <i>Hepatology Research</i> , 2002, 23, 265-273.	1.8	34